Von Willebrand Factor
Generic name: Von Willebrand Factor/coagulation factor viii complex (human)
Dosage form: powder for solution, for intravenous use
Drug class:Miscellaneous coagulation modifiers
Medically reviewed by Drugs.com. Last updated on Jul 22, 2021.
On This Page
- Indications and Usage
- Dosage and Administration
- Dosage Forms and Strengths
- Contraindications
- Warnings and Precautions
- Adverse Reactions/Side Effects
- Drug Interactions
- Use In Specific Populations
- Description
- Clinical Pharmacology
- Clinical Studies
- References
- How Supplied/Storage and Handling
- Patient Counseling Information
Indications and Usage for Von Willebrand Factor
Wilate is a Von Willebrand Factor/Coagulation Factor VIII Complex (Human) indicated for the treatment of spontaneous and trauma-induced bleeding episodes in patients with severe von Willebrand disease (VWD) as well as patients with mild or moderate VWD in whom the use of desmopressin is known or suspected to be ineffective or contraindicated.
Clinical trials to evaluate the safety and efficacy of prophylactic dosing with Wilate to prevent spontaneous bleeding have not been conducted in VWD subjects.
Wilate is not indicated for the prevention of excessive bleeding during and after surgery in VWD patients.
Wilate is not indicated for Hemophilia A.
Von Willebrand Factor Dosage and Administration
- For Intravenous Use after Reconstitution
- Treatment should be initiated under the supervision of a physician experienced in the treatment of coagulation disorders.
- Each vial of Wilate contains the labeled amount in International Units (IU) of Von Willebrand Factor (VWF) activity as measured with the Ristocetin cofactor assay (VWF:RCo), and coagulation factor VIII (FVIII) activity measured with the chromogenic substrate assay.
- The number of units of VWF:RCo and FVIII activities administered is expressed in IU, which are related to the current WHO standards for VWF and FVIII products. VWF:RCo and FVIII activities in plasma are expressed either as a percentage (relative to normal human plasma) or in IU (relative to the International Standards for VWF:RCo and FVIII activities in plasma).
Dosage in von Willebrand Disease
The ratio between VWF:RCo and FVIII activities in Wilate is approximately 1:1.
The dosage should be adjusted according to the extent and location of the bleeding. In VWD type 3 patients, especially in those with gastro-intestinal (GI) bl...
